Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615017 · ClinicalTrials.gov registry record · Phase 2
AZD9773 Dose Escalation Study
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00615017 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 70 participants.
The verdict
NCT00615017, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773) in adult patients with severe sepsis.
Interventions
- OTHER Placebo
- DRUG AZD9773 (CytoFab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615017
The ClinicalTrials.gov registry entry for NCT00615017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00615017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615017 about?
NCT00615017 is a clinical study titled "AZD9773 Dose Escalation Study". This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773) in adult patients with severe sepsis.
What is the current status of trial NCT00615017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2008-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00615017?
The interventions under investigation include: Placebo (OTHER), AZD9773 (CytoFab) (DRUG).
Who is sponsoring clinical trial NCT00615017?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.